Journal of Life Science (생명과학회지)

Korean Society of Life Science (한국생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Synergistic antitumor activity of ST1571 and camptothecin in human cancer cells

Camptothecin 에 의한 ST1571 의 항암 활성 증강

  • Kim, Mi-Ju (Department of Biochemistry, Pusan National University school of Medicine) ;
  • Lee, Sang-Min (Department of Biochemistry, Pusan National University school of Medicine) ;
  • Bae, Jae-Ho (Department of Biochemistry, Pusan National University school of Medicine) ;
  • Chung, Byung-Seon (Department of Biochemistry, Pusan National University school of Medicine) ;
  • Kang, Chi-Dug (Department of Biochemistry, Pusan National University school of Medicine) ;
  • Kim, Sun-Hee (Department of Biochemistry, Pusan National University school of Medicine)
  • 김미주 (부산대학교 의과대학 생화학교실) ;
  • 이상민 (부산대학교 의과대학 생화학교실) ;
  • 배재호 (부산대학교 의과대학 생화학교실) ;
  • 정병선 (부산대학교 의과대학 생화학교실) ;
  • 강치덕 (부산대학교 의과대학 생화학교실) ;
  • 김선희 (부산대학교 의과대학 생화학교실)
  • Published : 2007.06.25
Download PDF
⟨ Previous Next ⟩

Abstract

The in vitro activity of ST1571, an inhibitor of the Abl group of protein-tyrosine kinases, alone or in combination with camptothecin (CPT), a specific topoisomerase I inhibitor, was evaluated against human cancer cells with different metastatic capacity and drug resistance potency. These cell lines showed different sensitivity to ST157 on growth inhibition, and the expression of DNA-dependent protein kinase (DNA-PK), which interacts constitutively with c-Abl, was significantly decreased in drug sensitive CEM and MCF-7 cells and poorly metastatic PC3 and KMl2 cells as compared with that of multidrug resistant CEM/MDR and MCF-7/MDR cells and highly metastatic PC3-MM2 and KM/L4a cells, respectively. These results suggest differential modulation of DNA-PK by ST1571 treatment in drug resistance and metastatic degree dependent manner. We showed that CPT as well as ST1571 significantly inhibits the expression of DNA-PK. The combined treatment with ST15fl and CPT revealed synergistic effect, and the effect was accompanied by inhibition of cell proliferation due to significant reduced expression of DNA-PK components, which resulted in CPT sensitizes human cancer cells resistant to ST1571. Therefore, the results of our study suggested that the suppression of DNA-PK using combination of ST1571 and CPT could be a novel molecular target for against drugresistant and metastatic cancer cells.

본 연구에서는 전이성 암세포와 항암제 다제내성 세포에 있어서 항암제 내성에 영향을 미치는 것으로 알려진 DNA-dependent protein kinase (DNA-PK) 가 Abl protein-tyrosine kinases저해제인 STl571 내성에도 연관되어 있는지에 대하여 조사하였다. 또한 STl571 과 topoisomerase I 저해제인 camptothecin (CPT) 의 단독 및 병용처리에 의한 항암 활성을 전이성 암세포와 항암제 다제내성 세포를 대상으로 조사하였다. 세포의 전이도와 내성정도에 따라 STl571 의 감수성이 다르게 나타났다. 이와 함께 ST1571의 처리후 농도에 따라 전이도가 낮은 KMl2, PC3 세포와 항암제 감수성인 CEM, MCF-7 세포에서는 DNA-PK 의 발현이 감소하는 반면, 전이도가 높은 KML4a, PC-MM2 세포와 다제내성 CEM/MDR 및 MCR/MDR 세포에서는 그 발현이 증가되어 있음을 알 수 있었다. 이는 DNA-PK 의 발현이 STl571 의 내성에 관여한다는 것을 시사한다. 이와 같은 결과에 근거하여 DNA-PK 의 발현을 감소시키는 CPT를 STl571 내성을 나타내는 암세포에 대하여 STl571 과 병용처리 하였다. 그 결과 DNA-PK의 발현이 감소되고 세포증식이 억제됨으로써 ST1571 의 감수성이 CPT에 의해 증가하는 것을 알 수 있었다. 따라서 본 연구에서는 DNA-PK가 STl571 의 내성을 극복하는데 있어서 새로운 표적이 될 수 있으며, STl571 의 치료내성 극복에 CPT 와의 병용처리가 유효함을 알 수 있었다.

Keywords

References

  1. Perona, R. and I. Sanchez-Perez. 2004. Control of oncogenesis and cancer therapy resistance. Br. J. Cancer 90, 573-577 https://doi.org/10.1038/sj.bjc.6601552
  2. Kim, S. H., J. H. Um, D. W. Kim, B.H. Kwon, D. W. Kim, B. S. Chung, C. D. Kang and S. H. Kim. 2000. Potentiation of chemosensitivity in multidrug-resistant human leukemia CEM cells by inhibition of DNA-dependent protein kinase using wortmannin. Leuk. Res. 24, 917-925 https://doi.org/10.1016/S0145-2126(00)00061-8
  3. Um, J. H., J. K. Kwon, C. D. Kang, M. J., Kim, D. S. Ju, J. H. Bae, D. W. Kim, B. S. Chung and S. H. Kim. 2004. Relationship between antiapoptotic molecules and metastatic potency and the involvement of DNA-dependent protein kinase in the chemosensitization of metastatic human cancer cells by epidermal growth factor receptor blockade. J. Pharmacol. Exp. Ther. 311, 1062-1070 https://doi.org/10.1124/jpet.104.070938
  4. Shintani, S., M. Mihara, C. Li, Y. Nakahara, S. Hino, K.Nakashiro and H. Hamakawa. 2003. Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma. Cancer Sci. 94, 894-900 https://doi.org/10.1111/j.1349-7006.2003.tb01372.x
  5. Zhelev, Z., R. Bakalova, H. Ohba, A. Ewis, M. Ishikawa, Y. Shinohara and Y. Baba. 2004. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study). FEBS Lett. 570, 195-204 https://doi.org/10.1016/j.febslet.2004.06.048
  6. Kim, R. and T. Toge. 2004. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents. Surg. Today 34, 293-303 https://doi.org/10.1007/s00595-003-2710-4
  7. Pardanani, A. and A. Tefferi. 2004. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 104, 1931-1939 https://doi.org/10.1182/blood-2004-01-0246
  8. Fabbro, D., S. Ruetz, E. Buchdunger, S.W. Cowan-Jacob, G. Fendrich, J. Liebetanz, J. Mestan, T. O'Reilly, P. Traxler, B. Chaudhuri, H. Fretz, J. Zimmermann, T. Meyer, G. Caravatti, P. Furet and P. W. Manley. 2002. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther. 93, 79-98 https://doi.org/10.1016/S0163-7258(02)00179-1
  9. Slupianek, A., G. Hoser, I. Majsterek, A. Bronisz, M. Malecki, J. Blasiak, R. Fishel and T. Skorski. 2002. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol. Cell Biol. 22, 4189-4201 https://doi.org/10.1128/MCB.22.12.4189-4201.2002
  10. Russell, J. S., K. Brady, W. E. Burgan, M. A. Cerra, K. A. Oswald, K. Camphausen and P. J. Tofilon. 2003. Gleevecmediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res. 63, 7377-7383
  11. Adachi, N., S. So and H. Koyama. 2004. Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage. J. Biol. Chem. 279, 37343-37348 https://doi.org/10.1074/jbc.M313910200
  12. Mukai, M., X. F. Che, T. Furukawa, T. Sumizawa, S. Aoki, X. Q. Ren, M. Haraguchi, Y. Sugimoto, M. Kobayashi, H. Takamatsu and S.Akiyama. 2003. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. Cancer Sci. 94, 557-563 https://doi.org/10.1111/j.1349-7006.2003.tb01482.x
  13. Mahon, F. X., F. Belloc, V. Lagarde, C. Chollet, F. Moreau-Gaudry, J. Reiffers, J. M. Goldman and J.V. Melo. 2003. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101, 2368-2373 https://doi.org/10.1182/blood.V101.6.2368
  14. Tauchi, T. and K. Ohyashiki. 2004. Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leuk. Res, 28, 39-45 https://doi.org/10.1016/j.leukres.2003.10.007
  15. Panasci, L., J. P. Paiement, G. Christodoulopoulos, A. Belenkov, A. Malapetsa and R. Aloyz. 2001. Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin. Cancer Res. 7, 454-461
  16. Hansen, L. T., C. Lundin, T. Helleday, H. S. Poulsen, C. S. Sorensen, L. N. Petersen and M. Spang-Thomsen. 2003. DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer. Lung Cancer 40, 157-164 https://doi.org/10.1016/S0169-5002(03)00026-6
  17. Christodoulopoulos, G., C. Muller , B. Salles, R. Kazmi and L. Panasci. 1998. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin. Cancer Res. 58, 1789-1792
  18. Hashimoto, M., S. Rao, O. Tokuno, K. Yamamoto, M. Takata, S. Takeda and H. Utsumi. 2003. DNA-PK: the major target for wortmannin-mediated radiosensitization by the inhibition of DSB repair via NHEJ pathway. J. Radiat. Res. (Tokyo) 44, 151-159 https://doi.org/10.1269/jrr.44.151
  19. Kharbanda, S., Z. M. Yuan, R. Weichselbaum and D. Kufe. 1998. Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 17, 3309-3318 https://doi.org/10.1038/sj.onc.1202571
  20. Kano,Y., M. Akutsu, S. Tsunoda, H. Mano, Y. Honma and Y. Furukawa. 2001. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97, 1999-2007 https://doi.org/10.1182/blood.V97.7.1999
  21. Tipping, A. J., F. X. Mahon, G. Zafirides, V. Lagarde, J. M. Goldman and J. V. Melo. 2002. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 16, 2349-2357 https://doi.org/10.1038/sj.leu.2402775
  22. Zhou, X. Y. and Y. Wang. 2000. Inhibition of DNA replication in camptothecin-treated cells is regulated by protein kinases. Ann. N Y Acad. Sci. 922, 355-359 https://doi.org/10.1111/j.1749-6632.2000.tb07064.x
  23. Saijo, N. 2000. Preclinical and clinical trials of topoisomerase inhibitors. Ann. N Y Acad. Sci. 922, 92-99 https://doi.org/10.1111/j.1749-6632.2000.tb07028.x
  24. Wang, H., X. Wang, X. Y. Zhou, D. J. Chen, G. C. Li, G. Iliakis and Y. Wang. 2002. Ku affects the ataxia and Rad 3-related/CHK1-dependent S phase checkpoint response after camptothecin treatment. Cancer Res. 62, 2483-2487